I will create a structured therapeutic area overview and disease landscape report

Biopharma deals move fast licensing agreements, M&A, and royalty structures get announced with limited detail, and the strategic logic behind them is easy to miss if you're not tracking the space closely.

I turn public deal disclosures into structured, decision-ready intelligence. Working from press releases, SEC filings, and deal databases, I map the terms, valuation logic, and strategic rationale behind biopharma transactions in your area of interest.

What you get:

1. Deal terms breakdown upfront, milestones, royalties, structure
2. Strategic rationale, why this deal, why now, what it signals
3. Comparable deals benchmarking within the therapeutic area
4. Sourced writing every figure traceable to a public filing

Who this is for: investors building a thesis, BD teams scoping partnerships, and biotech teams benchmarking their own deal terms against the market.

Background: 6+ years in pharma competitive intelligence, incl. a 33-slide investor-grade licensing and platform analysis for a biotech investor client. Strict no-fabrication standard, every data point sourced, gaps flagged not filled.

Message me before ordering to confirm scope and companies.